ACKR3 and renal cell carcinoma: Similarly, a newly discovered CXCL12 receptor, CXCR7, is highly expressed in RCC patients, indicating that CXCR7 may be useful a novel surface marker and therapeutic target for RCC (Maishi et al., 2012; Wang et al., 2012a).